Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New platelet inhibitors].

M Spannagl1, L Frey

  • 1Medizinische Klinik Innenstadt der LMU, Ziemssenstrasse 1, 80336 München.

Der Anaesthesist
|April 24, 2001
PubMed
Summary
This summary is machine-generated.

New antiplatelet agents like thienopyridines and glycoprotein IIb/IIIa inhibitors offer alternatives to aspirin in vascular medicine. Careful consideration of bleeding risks and management strategies is crucial when using these potent platelet inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biaxial Piezoelectric MEMS Mirrors with Low Absorption Coating for 1550 nm Long-Range LIDAR.

Micromachines·2023
Same author

First Comparison of Retroperitoneal Versus Transperitoneal Robot-Assisted Nephroureterectomy with Bladder Cuff: A Single Center Study.

Annals of surgical oncology·2023
Same author

Assessment of a novel smartglass-based point-of-care fusion approach for mixed reality-assisted targeted prostate biopsy: A pilot proof-of-concept study.

Frontiers in surgery·2022
Same author

[Virtual and augmented reality in urology].

Der Urologe. Ausg. A·2021
Same author

[Anticoagulation in patients with COVID-19].

Der Internist·2021
Same author

Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients.

Thrombosis research·2020
Same journal

[Promoting young academics in anesthesiology: factors for an attractive internship].

Der Anaesthesist·2022
Same journal

[Respiratory support in COVID-19: all in due time!]

Der Anaesthesist·2022
Same journal

[Noninvasive respiratory support and invasive ventilation in COVID‑19 : Where do we stand today?]

Der Anaesthesist·2022
Same journal

[Management of acutely decompensated liver cirrhosis in emergency and critical care medicine].

Der Anaesthesist·2022
Same journal

[Anesthesia in patients with acute porphyria].

Der Anaesthesist·2022
Same journal

[Quality and safe anesthesia for all children : That is their right!]

Der Anaesthesist·2022
See all related articles

Area of Science:

  • Pharmacology
  • Vascular Medicine
  • Hematology

Context:

  • Acetylsalicylic acid is a primary antiplatelet agent in vascular medicine.
  • Emergence of novel antiplatelet therapies including thienopyridines and glycoprotein IIb/IIIa inhibitors.
  • These agents target adenosine diphosphate (ADP)-induced platelet aggregation and platelet aggregation via glycoprotein IIb/IIIa receptors.

Purpose:

  • To review the current landscape of antiplatelet agents beyond acetylsalicylic acid.
  • To discuss the mechanisms, efficacy, and clinical applications of thienopyridines and glycoprotein IIb/IIIa inhibitors.
  • To highlight the importance of managing bleeding complications associated with these potent antiplatelet therapies.

Summary:

  • Thienopyridines (e.g., Ticlopidine, Clopidogrel) inhibit ADP-induced platelet aggregation with prolonged effects.

Related Experiment Videos

  • Intravenous Glycoprotein IIb/IIIa inhibitors offer short-acting potent platelet inhibition, improving acute coronary syndrome management.
  • Combination therapy with antiplatelet agents and heparins is common, necessitating vigilance for bleeding risks.

    • Impact:

    • These advancements provide enhanced therapeutic options for preventing thrombotic events.
    • Understanding the pharmacodynamics and potential adverse effects is critical for optimizing patient care.
    • Strategies for immediate reversal of antiplatelet effects, such as hemodialysis or platelet concentrates, are essential for managing emergent bleeding complications.